Monitor the ASCO poster presentation on May 30 for early signs of safety, tolerability, and anti-tumor activity of OP-3136, which could de-risk the asset and provide a near-term catalyst for re-rating. Absent efficacy signals, sentiment may remain muted despite the event.
OLMA drugs
OLMA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 22 $16.24entry
- T+1 · 7mo ago −5.48%α −5.09% · $15.35
- T+5 · 7mo ago −12.32%α −12.37% · $14.24
- T+20 · 6mo ago −19.34%α −22.50% · $13.10
- T+60 · 4mo ago −29.37%α −34.15% · $11.47
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Olema Oncology announced upcoming presentations of initial Phase 1 data for OP-3136 and a trial-in-progress overview of its Phase 3 OPERA-02 study at ASCO 2026. The data readout for OP-3136, a novel KAT6 inhibitor, represents an early clinical milestone for the pipeline beyond its lead candidate palazestrant.
Key Facts
- Olema Oncology will present initial Phase 1 clinical data for OP-3136 at ASCO 2026 on May 30, 2026.
- OP-3136 is a novel oral selective KAT6A/B inhibitor being studied in advanced solid tumors and ER+, HER2− breast cancer.
- The company will also present a trial-in-progress poster for the Phase 3 OPERA-02 study of palazestrant plus ribociclib in ER+, HER2− advanced breast cancer on June 1, 2026.
- OP-3136 received FDA IND clearance in December 2024; enrollment is ongoing in the Phase 1 study.
- Palazestrant has FDA Fast Track designation and is in two ongoing Phase 3 trials (OPERA-01 and OPERA-02).
Financial Impact
No financial impact in near term; data readout may influence valuation based on clinical signal.
Risk Factors
- Early-phase data may show limited clinical activity or safety concerns, leading to negative sentiment.
- Lack of near-term commercial catalysts for OP-3136 given its early development stage.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278398 |
Track record
20 reports on OLMA
1 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +38.44% at T+60 after the Aug 9, 2026 report. 1 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.29 Now $7.36 +0.96% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 2/10 Entry $7.56 Now $7.36 −2.65% settles Feb 11
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $7.27 Now $7.36 +1.24% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $7.33 Now $7.36 +0.41% settles Feb 4
- Oct 16, 20264w ago SC 13D/A Neutral 2/10 Entry $7.11 Now $7.36 +3.52% settles Jan 14
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $6.58 Now $7.36 +11.85% settles Jan 13
- Oct 2, 20266w ago Press Release Neutral 2/10 Entry $8.25 Now $7.36 −10.79% settles Dec 30
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 4/10 Entry $10.43 to $7.54 Now $7.36 −29.43% ▼ −27.71% −27.22% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bearish 6/10 Entry $11.94 to $7.35 Now $7.36 +38.36% ▲ +38.44% +36.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers